起始胰岛素泵治疗对使用多次每日胰岛素注射和连续血糖监测的1型糖尿病成人的影响(DIAMOND):多中心随机对照试验
DIAMOND试验纳入75例使用CGM的1型糖尿病成人,随机分为继续MDI或换用CSII并继续CGM,随访28周。CSII组血糖在70-180 mg/dL的时间较MDI组增加83分钟/日(95%CI 17-149;p=0.01),但低血糖也增加。
要点
- 在使用CGM的1型糖尿病成人中,起始CSII可改善血糖范围内时间。
- CSII组CGM测得的低血糖增加,将结果用于临床实践时需考虑。
- 两组HbA1c变化无显著差异(p=0.32)。
核心结论
- 在1型糖尿病成人中,起始CSII可改善CGM测得的70-180 mg/dL范围内时间。
- 但研究中生化低血糖也增加,将结果用于临床实践时需考虑。
研究设计与样本
- 多中心随机对照试验,75例使用CGM的1型糖尿病成人随机分为继续MDI或换用CSII并继续CGM,随访28周。
- 主要结局为CGM测得的血糖浓度在70-180 mg/dL(3.9-10.0 mmol/L)范围内的时间。
- 试验注册号NCT02282397。
主要发现
- 2015年4月14日至2016年5月5日,37例随机分入CGM+CSII组,38例分入CGM+MDI组。
- CGM+CSII组36/37例(97%)完成研究,CGM+MDI组35/38例(92%)完成研究。
- CGM+CSII组平均CGM使用为每周6.7天(SD 0.8),CGM+MDI组为每周6.9天(SD 0.3)(p=0.86)。
- CGM+CSII组完成试验者中无人终止CSII。
- 随访期间,CGM+CSII组血糖在70-180 mg/dL范围内平均时间为791分钟/日(SD 157),CGM+MDI组为741分钟/日(SD 225),校正后平均治疗组差异为83分钟(95%CI 17-149;p=0.01)。
临床怎么用
- 作者认为,将上述结果纳入临床实践时,需考虑CSII起始后生化低血糖增加这一情况。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of initiation of insulin pump therapy (continuous subcutaneous insulin infusion; CSII) in patients with type 1 diabetes using continuous glucose monitoring (CGM) has not been studied. We aimed to assess glycaemic outcomes when switching from multiple daily injections (MDI) to CSII in adults with type 1 diabetes using CGM. METHODS: In this multicentre, randomised controlled trial, 75 adults with type 1 diabetes in the CGM group of the DIAMOND trial were randomly assigned via the study website using a computer-generated sequence to continue MDI or switch to CSII, with continuation of CGM, for 28 weeks. The primary outcome was CGM-measured time in the glucose concentration range of 70-180 mg/dL (3·9-10·0 mmol/L). This study is registered with ClinicalTrials.gov, number NCT02282397. FINDINGS: Between April 14, 2015, and May 5, 2016, 37 participants were randomly assigned to the CGM plus CSII group and 38 participants were randomly assigned to the CGM plus MDI group. The study was completed by 36 (97%) of 37 participants in the CGM plus CSII group and 35 (92%) of 38 participants in the CGM plus MDI group. Mean CGM use was 6·7 days per week (SD 0·8) in the CGM plus CSII group and 6·9 days per week (0·3) in the CGM plus MDI group (p=0·86). No participants in the CGM plus CSII group who completed the trial discontinued CSII. Over the follow-up period, mean time in the glucose concentration range of 70-180 mg/dL (3·9-10·0 mmol/L) was 791 min per day (SD 157) in the CGM plus CSII group and 741 min per day (225) in the CGM plus MDI group (adjusted mean treatment group difference: 83 min, 95% CI 17-149; p=0·01). Participants in the CGM plus CSII group had a greater reduction in CGM-measured mean glucose (p=0·005) and hyperglycaemia (on four metrics: p=0·007 for >180 mg/dL [>10·0 mmol/L], p=0·02 for >250 mg/dL [>13·9 mmol/L], p=0·04 for >300 mg/dL [>16·6 mmol/L], and p=0·02 for the area under the curve for 180 mg/dL [10·0 mmol/L]), but also an increase in CGM-measured hypoglycaemia (p=0·0001 for <70 mg/dL [<3·9 mmol/L], p=0·0002 for <60 mg/dL [<3·3 mmol/L], p=0·0009 for <50 mg/dL [<2·8 mmol/L], p=0·0002 for the area over the curve for 70 mg/dL [3·9 mmol/L]). Mean HbA1c change from baseline to 28 weeks was 0·3% (SD 0·9; 3·3 mmol/mol [SD 9·8]) in the CGM plus CSII group and 0·1% (0·4; 1·1 mmol/mol [4·4]) in the CGM plus MDI group (p=0·32). Severe hypoglycaemia occurred in one participant in the CGM plus MDI group, and diabetic ketoacidosis and severe hyperglycaemia occurred in one participant each in the CGM plus CSII group. INTERPRETATION: Our findings show that glycaemic control measured by time in the glucose range of 70-180 mg/dL (3·9-10·0 mmol/L) is improved by initiation of CSII in adults with type 1 diabetes. However, biochemical hypoglycaemia also was increased in the study, which will be important to consider when incorporating these results into clinical practice. FUNDING: Dexcom.
引用
- Beck RW, Riddlesworth TD, Ruedy KJ, et al. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2017. PMID: 28711468. doi:10.1016/S2213-8587(17)30217-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。